Repligen (RGEN) Lags Q2 Earnings Estimates
Repligen (RGEN) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.33 per share a year ago.
Here's Why Repligen (RGEN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Jacob Johnson - VP, IR Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Dan Arias - Stifel Puneet Souda - Leerink Partners Justin Bowers - Deutsche Bank Subbu Nambi - Guggenheim Securities Brendan Smith - TD Cowen Doug Schenkel - Wolf Research Matt Stanton - Jefferies Dan Leonard - UBS Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's First Quarter of 2025 Earnings Conference Call. My name is Dorwin, and I will be your coordinator.
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates
Repligen (RGEN) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.28 per share a year ago.
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth
Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Repligen: Ongoing Bioprocessing Market Recovery
I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings.
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
RGEN reports decent fourth-quarter results and issues guidance for 2025.
Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q4 2024 Earnings Call Transcript February 20, 2025 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Matt Hewitt - Craig Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen.
